VRTX · News · 20261103N

Regulatory Approval Milestones

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 40 · Surprise 42

Vertex leaders expressed high confidence in the upcoming FDA decision on povetacicept, its investigational treatment for IgA nephropathy. The drug’s PDUFA date is upcoming, though the digest does not specify the date. Vertex expects the decision to precede a potential launch and views the treatment as a key driver of a future renal franchise.

Key facts

• BMO Capital cited anticipated regulatory approval and favorable labeling for Vertex's povetacicept, supported by ongoing communication with regulators and a safety, efficacy and CMC package. source